Drug intelligence / Profile preview

tarcidomgen kimleucel

Development stage: Phase 1
Lead developer: FamiCordTx
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

Tarcidomgen kimleucel is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by FamiCordTx, a subsidiary of FamiCord Group. It consists of autologous T lymphocytes genetically modified to express anti-CD19 CAR molecules, enabling targeted immunologic cytotoxicity against CD19-positive B-cell malignancies. The therapy is currently in Phase I clinical trials for the treatment of various B-cell neoplasms, including B-cell lymphoma, mantle-cell lymphoma, diffuse large B cell lymphoma, and precursor B-cell lymphoblastic leukemia-lymphoma. The drug acts as a gene therapy and immunotherapy by replacing or supplementing the patient’s own T lymphocytes with engineered cells capable of recognizing and destroying malignant cells expressing CD19[1][2][3][4][5][7].

Other names: tarcidomgen kimleucel

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on tarcidomgen kimleucel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tarcidomgen kimleucel.

Explore the full profile